The global glaucoma treatment market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). With the increasing prevalence of glaucoma among the geriatric population the demand for its treatment has been an increase. Therefore, the increasing approvals of the drugs for the treatment of glaucoma diseases are offering opportunities for market growth. For instance, in February 2021, Bausch health companies Inc., and Nicox, an ophthalmology company had received US FDA approval for VYZULTA, a latanoprostene bunod ophthalmic solution. This drug is for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma in the US. VYUZULTA is an important drug used for the treatment of glaucoma and now it is approved in nine markets including Canada, Argentina, Colombia, Taiwan, Hong Kong, Mexico, South Korea, Ukraine, and the US.
Browse the full report description of "Global Glaucoma Treatment Market Size, Share & Trends Analysis Report By Disease Indication (Closed Angle Glaucoma (CAG), Open Angle Glaucoma (OAG), Secondary Glaucoma, and Congenital Glaucoma), By Distribution Channel (Hospitals PHARMACY, RETAIL Pharmacy, and Online Pharmacy), By Drug Class (Prostaglandin Analogues, Alpha Agonist, Cholinergic, Beta Blockers, and Carbonic Anhydrase Inhibitors), Forecast Period 2021-2027" at https://www.omrglobal.com/industry-reports/glaucoma-treatment-market
Further, in July 2019, Allergan Plc, a pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Bimatoprost sustained-release (SR). The NDA is focused on the promising outcomes of the ARTEMIS phase 3 trials, and it shows our continued commitment to developing alternative therapies for glaucoma patients. Apart from it, in September 2020, Aerie Pharmaceuticals Inc., an ophthalmic pharmaceutical company focused on drugs for the treatment of eye-related disease, has announced that FDA has approved a new drug application (NDA), and AR-15512 eye drop for dry eye. Thus, the huge US FDA approvals for glaucoma treatment and various initiatives in drugs by the companies for the treatment of disease are driving the global market growth during the forecast period.
Market Coverage
o By Disease Indication
o By Distribution Channel
o By Drug Class
o North America
o Europe
o Asia-Pacific
o Rest of the World
Recent Strategies initiatives in the Global Glaucoma Treatment Market:
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Glaucoma Treatment Market Report Segment
By Disease Indication
By Distribution Channel
By Drug Class
Global Glaucoma Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/glaucoma-treatment-market